193 related articles for article (PubMed ID: 22669575)
1. AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer.
Brunckhorst MK; Lerner D; Wang S; Yu Q
Cancer Biol Ther; 2012 Jul; 13(9):804-11. PubMed ID: 22669575
[TBL] [Abstract][Full Text] [Related]
2. DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death.
Thibault B; Genre L; Le Naour A; Broca C; Mery E; Vuagniaux G; Delord JP; Wiedemann N; Couderc B
Sci Rep; 2018 Dec; 8(1):17862. PubMed ID: 30552344
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
4. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
5. FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.
Kreitzburg KM; Fehling SC; Landen CN; Gamblin TL; Vance RB; Arend RC; Katre AA; Oliver PG; van Waardenburg RCAM; Alvarez RD; Yoon KJ
Cancer Lett; 2018 Nov; 436():75-86. PubMed ID: 30120964
[TBL] [Abstract][Full Text] [Related]
6. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.
Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D
Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656
[TBL] [Abstract][Full Text] [Related]
7. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin.
Scalici JM; Harrer C; Allen A; Jazaeri A; Atkins KA; McLachlan KR; Slack-Davis JK
Gynecol Oncol; 2014 Feb; 132(2):455-61. PubMed ID: 24378876
[TBL] [Abstract][Full Text] [Related]
10. Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer.
Liu J; Agopiantz M; Poupon J; Wu Z; Just PA; Borghese B; Ségal-Bendirdjian E; Gauchotte G; Gompel A; Forgez P
Clin Cancer Res; 2017 Nov; 23(21):6516-6528. PubMed ID: 28790113
[No Abstract] [Full Text] [Related]
11. An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer.
Janzen DM; Tiourin E; Salehi JA; Paik DY; Lu J; Pellegrini M; Memarzadeh S
Nat Commun; 2015 Aug; 6():7956. PubMed ID: 26234182
[TBL] [Abstract][Full Text] [Related]
12. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.
Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY
Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295
[TBL] [Abstract][Full Text] [Related]
13. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
14. The small-molecule IAP antagonist AT406 inhibits pancreatic cancer cells in vitro and in vivo.
Jiang Y; Meng Q; Chen B; Shen H; Yan B; Sun B
Biochem Biophys Res Commun; 2016 Sep; 478(1):293-299. PubMed ID: 27387230
[TBL] [Abstract][Full Text] [Related]
15. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
[TBL] [Abstract][Full Text] [Related]
16. Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer.
El-Gazzar A; Perco P; Eckelhart E; Anees M; Sexl V; Mayer B; Liu Y; Mikulits W; Horvat R; Pangerl T; Zheng D; Krainer M
Mol Cancer Ther; 2010 Apr; 9(4):1007-18. PubMed ID: 20371719
[TBL] [Abstract][Full Text] [Related]
17. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
[TBL] [Abstract][Full Text] [Related]
18. T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
Dziegielewska B; Casarez EV; Yang WZ; Gray LS; Dziegielewski J; Slack-Davis JK
Mol Cancer Ther; 2016 Mar; 15(3):460-70. PubMed ID: 26832797
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
20. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
